Instead of improving the patent system, the PTAB has turned it into a prime example of regulatory overreach by imposing tremendous costs and creating uncertainty for the innovation economy. #CPIPspotlight #PatentsMatter #FixPTAB READ: regproject.org/paper/cripplin…
Despite the lack of evidence of harm, IEEE recently implemented restrictions that have harmed innovators—with the blessing of the Antitrust Division. As Gregory Sidak argues, this was a dereliction of duty. #CPIPspotlight #FactsNotRhetoric #IPMatters READ: cpip.gmu.edu/2018/10/10/ip-…
'No empirical study has demonstrated that a patent-owner’s request for injunctive relief . . . has ever resulted either in consumer harm or in slowing down the pace of technological innovation.” #CPIPspotlight #FactsNotRhetoric #PatentsMatter READ: cpip.gmu.edu/wp-content/upl…
'Before rushing to implement a marginal cost pricing system, proponents would be wise to consider the drastic effects it could have on incentives to innovate—and ultimately the development of the next ground-breaking drugs.' #CPIPspotlight #IPMatters READ: cpip.gmu.edu/2018/11/29/fla…
'Given the well understood role that innovation plays in facilitating economic growth, a heavy burden of proof rests on those who insist on the centrality of 'patent holdup' to offer some tangible support for that view.' #CPIPspotlight #FactsNotRhetoric cpip.gmu.edu/2018/02/13/let…
CPIP Founder Adam Mossoff to FTC: 'For over two hundred years, reliable and effective intellectual property rights have facilitated dynamic efficiency and growth in innovation markets in the U.S. economy.' #CPIPspotlight #FactsNotRhetoric #IPMatters cpip.gmu.edu/wp-content/upl…
Finding a new use for a known drug takes time & money—up to 5 years and $300 million. But as CPIP Senior Scholar paul lietzan explains, incentives for such #innovation are often nothing but paper promises. #CPIPspotlight #PatentsMatter #FactsNotRhetoric READ: ssrn.com/abstract=31032…
The IEEE should reconsider its patent policy in light of actual evidence and return back to the balanced policy that successfully promoted the computer and mobile revolutions of the past four decades. #CPIPspotlight #FactsNotRhetoric #PatentsMatter READ: cpip.gmu.edu/2018/07/17/stu…
'§ 1498 does not grant the government a new power to authorize infringement of a patent for the sole purpose of a company selling a product at a lower price in the market, effectively imposing de facto government price controls on drugs.' #CPIPspotlight cpip.gmu.edu/2018/11/05/pro…
CPIP's Chris Katopis: 'Section 1498(a) is not a 'Groupon' for discounted federal shopping sprees' | Recognizing the Limits of Government Procurement in the Pharmaceutical Industries #CPIPspotlight #PatentsMatter READ: cpip.gmu.edu/2018/12/20/rec…
Section 1498 is not a price control mechanism—it’s not a “Groupon” for discounted federal shopping sprees. Using eminent domain power to procure discounted drugs would deprive patent owners of their rights and threaten #innovation . #CPIPspotlight READ: cpip.gmu.edu/2018/12/20/rec…
Regulatory overreach in the past decade has diminished the patent property right and has called into question the value and enforceability of these rights—and we are losing our innovative edge. #CPIPspotlight #PatentsMatter regproject.org/paper/will-ove…
After the #OilStates decision, #fixPTAB reform moves to Congress & USPTO. Reform is necessary, bc PTAB was structurally flawed from get-go, in part bc based in mistaken rhetoric about prevalence of 'bad patents.' READ: lawdigitalcommons.bc.edu/bclr/vol56/iss… … #CPIPspotlight #CPIPscholars
CPIP's @ProfSeanOConnor Files Comments with FTC on Consumer and Competition Concerns with Copyright Licensing #CPIPspotlight #FactsNotRhetoric #CopyrightsMatter cpip.gmu.edu/2019/01/08/cpi…
The FTC’s overreach in the pharmaceutical industry harms consumers in the short run by slowing access to drugs and in the long run by weakening innovation. #CPIPspotlight #FactsNotRhetoric #Innovation READ: cpip.gmu.edu/2019/01/09/cpi…
CPIP Scholars Join Comment Letter to FTC Supporting Evidence-Based Approach to IP Policymaking #CPIPspotlight #FactsNotRhetoric #Innovation cpip.gmu.edu/2019/01/07/cpi…
CPIP Scholars Join Comments to FTC on How Antitrust Overreach is Threatening Healthcare Innovation #CPIPspotlight #FactsNotRhetoric #Innovation cpip.gmu.edu/2019/01/09/cpi…
CPIP's Kevin R. Madigan: 'Government mandated marginal cost pricing schemes implemented through § 1498 would threaten innovators’ ability to both recoup past losses and to fund the development of new technology.' #CPIPspotlight READ: cpip.gmu.edu/2018/11/29/fla…
READ: New paper by Prof. paul lietzan destroys myth Hatch-Waxman was win-win for generics & pharma cos. It was loss for drug innovators due to lobbying alliance of advocacy groups & generics ala classic public choice theory. Read the real story! ssrn.com/abstract=31401… #CPIPspotlight